<div id="readability-page-1">Portage, Michigan, April 13, 2026 (GLOBE NEWSWIRE) -- Stryker , a global leader in medical technologies, announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease. The acquisition will strengthen Stryker’s Peripheral Vascular (PV) portfolio by adding revascularization technology. Once cleared for use in applicable markets, the product will complement Stryker’s existing PV offerings and support the company’s strategy to expand its presence in arterial disease treatment. “This acquisition represents an important step in advancing our vision to build a comprehensive peripheral vascular platform and address significant unmet clinical needs,” said Kevin Lobo, Chair and CEO, Stryker. “Combining this innovation with Stryker’s scale and clinical expertise, we believe we can help expand treatment options for physicians and improve care for patients with calcified peripheral arterial disease.” AVS’ technology is designed to use pulsed CO₂-generated pressure waves uniformly delivered through an IVL balloon catheter, to fracture calcium and optimize luminal gain. The platform is designed to enhance catheter deliverability, treatment speed and therapy efficiency. IVL is a fast-growing technology in cardiovascular intervention and is used to treat calcified peripheral and coronary lesions. It is expected to experience strong growth as physicians adopt IVL-based calcium modification in complex procedures. This transaction is subject to customary closing conditions. Stryker and AVS will continue to operate as separate entities and proceed with business as usual until the transaction closes. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com. About Amplitude Vascular Systems (AVS) Amplitude Vascular Systems (AVS) is a medical device company based in Boston, Mass., focused on treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital, Cue Growth Partners, and others. It was founded in 2017 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at the University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. More information is available at www.avspulse.com. Contacts For investor inquiries: Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or jason.beach@stryker.com For media inquiries: Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com Image: https://www.globenewswire.com/newsroom/ti?nf=OTY4ODEyMiM3NTMwOTIwIzIwMDgzMjg= Image: https://ml.globenewswire.com/media/ZDI0M2FkMjktOTYxOS00ZWI1LWI0MTItZTVjYTFjY2U3OWRmLTEwMTk5MDEtMjAyNi0wNC0xMy1lbg==/tiny/Stryker-Corporation.png Image: Primary Logo Source: Stryker Corporation ( SYK )</div>

史赛克

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

史赛克已签署一项最终协议，收购 Amplitude Vascular Systems，增强其外周血管产品组合，加入下一代血管内碎石（IVL）技术。此次收购旨在满足治疗钙化外周动脉疾病的未满足临床需求。IVL 平台利用脉冲二氧化碳生成的压力波来优化治疗效率。该交易需满足惯例的成交条件，双方公司将在交易完成之前继续独立运营。史赛克首席执行官 Kevin Lobo 强调了此次收购在扩大患者治疗选择方面的重要性

史赛克签署了最终协议，收购 Amplitude Vascular Systems，以将下一代 IVL 技术纳入其外周血管产品组合